Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
The Coronavirus Disease 2019 (COVID-19) pandemic is still spreading worldwide over 2 years since its outbreak. The psychopathological implications in COVID-19 survivors such as depression, anxiety, and cognitive impairments are now recognized as primary symptoms of the “post-acute COVID-19 syndrome.” Depressive psychopathology was reported in around 35% of patients at short, medium, and long-term follow-up after the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. Post-COVID-19 depressive symptoms are known to increase fatigue and affect neurocognitive functioning, sleep, quality of life, and global functioning in COVID-19 survivors. The psychopathological mechanisms underlying post-COVID-19 depressive symptoms are mainly related to the inflammation triggered by the peripheral immune-inflammatory response to the viral infection and to the persistent psychological burden during and after infection. The large number of SARS-CoV-2-infected patients and the high prevalence of post-COVID-19 depressive symptoms may significantly increase the pool of people suffering from depressive disorders. Therefore, it is essential to screen, diagnose, treat, and monitor COVID-19 survivors’ psychopathology to counteract the depression disease burden and related years of life lived with disability. This paper reviews the current literature in order to synthesize the available evidence regarding epidemiology, clinical features, neurobiological underpinning, and pharmacological treatment of post-COVID-19 depressive symptoms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32656-8 · Cited by 4,084
RetractedFrom inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395
Santomauro, D. F., Mantilla Herrera, A. M., Shadid, J., Zheng, P., Ashbaugh, C., Pigott, D. M., Abbafati, C., Adolph, C., Amlag, J. O., Aravkin, A. Y., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02143-7 · Cited by 5,444 · cited 1×
“These weaknesses, however, do not bias the main finding that the burden of post-COVID-19 depressive symptoms substantially exceeds the pre-pandemic epidemiology of this adverse psychopathological condition [11, 22, 25].”
BackgroundNalbandian, A., Sehgal, K., Gupta, A., Madhavan, M. V., McGroder, C., Stevens, J. S., Cook, J. R., Nordvig, A. S., Shalev, D., Sehrawat, T. S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01283-z · Cited by 4,862 · cited 3×
“Apart from acute infection, as previously observed in the SARS and the Middle East Respiratory Syndrome (MERS) outbreak, long-term neuropsychiatric sequelae of COVID-19 are now listed as the main symptoms of the post-acute COVID-19 syndrome [3].”
BackgroundInfluentialInflammation and Its Discontents: The Role of Cytokines in the Pathophysiology of Major Depression
Miller, A. H., Maletic, V., & Raison, C. L. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.11.029 · Cited by 3,848 · cited 1×
“Inflammatory cytokines may also directly influence glutamate signaling by stimulating the release of glutamate from astrocytes [77] and by decreasing its uptake, reducing the astrocytic expression of glutamate transporters [78].”
BackgroundThe pathogenesis and treatment of the `Cytokine Storm' in COVID-19
Ye, Q., Wang, B., & Mao, J. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.03.037 · Cited by 2,761
Rogers, J. P., Chesney, E., Oliver, D., Pollak, T. A., McGuire, P., Fusar-Poli, P., Zandi, M. S., Lewis, G., & David, A. S. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30203-0 · Cited by 2,407
Li, Y., Bai, W., & Hashikawa, T. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25728 · Cited by 2,266
Taquet, M., Geddes, J. R., Husain, M., Luciano, S., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(21)00084-5 · Cited by 2,189 · cited 1×
“These weaknesses, however, do not bias the main finding that the burden of post-COVID-19 depressive symptoms substantially exceeds the pre-pandemic epidemiology of this adverse psychopathological condition [11, 22, 25].”
BackgroundNervous system involvement after infection with COVID-19 and other coronaviruses
Wu, Y., Xu, X., Chen, Z., Duan, J., Hashimoto, K., Yang, L., Liu, C., & Yang, C. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.03.031 · Cited by 2,046 · cited 1×
“The pathogenesis of the neuropsychiatric manifestations of COVID-19 has been suggested to be mainly a result of central nervous system (CNS) indirect immune-inflammatory-mediated damage and, hypothetically, a potential consequence of direct viral neuroinvasion [16, 40].”
BackgroundWhy is depression more prevalent in women?
Albert, P. R. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150205 · Cited by 1,785 · cited 1×
“We have to consider that while males are at higher risk of COVID-19 severe outcome and related higher inflammatory response [121], females have a higher risk of developing depression than males [122].”
BackgroundSingh, S., Roy, D., Sinha, K., Parveen, S., Sharma, G., & Joshi, G. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113429 · Cited by 1,727 · cited 1×
“Social isolation, quarantine, uncertainty about the future, wide exposure to media, and survivor guilt experienced by infected patients may induce depressive symptoms following the infection [97, 98].”
BackgroundSynaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715
Wake, H., Moorhouse, A. J., Jinno, S., Kohsaka, S., & Nabekura, J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-08.2009 · Cited by 1,619
Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis
Ceban, F., Ling, S., Lui, L. M. W., Lee, Y., Gill, H., Teopiz, K. M., Rodrigues, N. B., Subramaniapillai, M., Di Vincenzo, J. D., Cao, B., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.12.020 · Cited by 1,554 · cited 3×
“The reported evidence suggests a central role of depressive psychopathology, which seems to be one of the most relevant predictors of both cognitive impairment and fatigue, which persist over time in almost a third of COVID-19 survivors [37].”
BackgroundInfluentialMale sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission
Peckham, H., de Gruijter, N. M., Raine, C., Radziszewska, A., Ciurtin, C., Wedderburn, L. R., Rosser, E. C., Webb, K., & Deakin, C. T. (2020) · Nature Communications · doi:10.1038/s41467-020-19741-6 · Cited by 1,503
Nemeroff, C. B., Widerlöv, E., Bissette, G., Walléus, H., Karlsson, I., Eklund, K., Kilts, C. D., Loosen, P. T., & Vale, W. (1984) · Science · doi:10.1126/science.6334362 · Cited by 1,485
Taquet, M., Luciano, S., Geddes, J. R., & Harrison, P. J. (2021) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30462-4 · Cited by 1,484
Immune modulation of learning, memory, neural plasticity and neurogenesis
Yirmiya, R., & Goshen, I. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.015 · Cited by 1,483
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series
Matschke, J., Lütgehetmann, M., Hagel, C., Sperhake, J. P., Schröder, A. S., Edler, C., Mushumba, H., Fitzek, A., Allweiss, L., Dandri, M., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30308-2 · Cited by 1,300
Coperchini, F., Chiovato, L., Croce, L., Magri, F., & Rotondi, M. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.05.003 · Cited by 1,288 · cited 4×
“Among cytokines, the most investigated were IL-6 [34, 111–115, 118, 119], IL-10 [34, 111, 112, 120], and TNF-α [111, 112, 118, 120].”
BackgroundInfluentialNeuropilin-1 is a host factor for SARS-CoV-2 infection
Daly, J. L., Simonetti, B., Klein, K., Chen, K.-E., Williamson, M. K., Antón-Plágaro, C., Shoemark, D. K., Simón-Gracia, L., Bauer, M., Hollandi, R., et al. (2020) · Science · doi:10.1126/science.abd3072 · Cited by 1,251
13 reasons why the brain is susceptible to oxidative stress
Cobley, J. N., Fiorello, M. L., & Bailey, D. M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.01.008 · Cited by 1,215 · cited 1×
“Brain cells are particularly vulnerable to oxidative stress [85], and low levels of antioxidants together with high levels of oxidative stress biomarkers have been consistently reported in MDD [86].”
BackgroundInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172 · cited 6×
“In this context, neuroinflammation and subsequent BBB disruption, neurotransmission impairment, HPA axis dysfunction, microglia activation, and indoleamine 2,3-dioxygenase (IDO) induction, all represent interaction pathways between SARS-CoV-2 infection and psychopathological mechanisms underpinning depressive disorder…”
BackgroundInfluentialRole of Pro-Inflammatory Cytokines Released from Microglia in Neurodegenerative Diseases
Smith, J. A., Das, A., Ray, S. K., & Banik, N. L. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.10.004 · Cited by 1,165
Maes, M., Galecki, P., Chang, Y. S., & Berk, M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.004 · Cited by 1,140
Wu, T., Jia, X., Shi, H., Niu, J., Yin, X., Xie, J., & Wang, X. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.11.117 · Cited by 1,138
Neuroimmune Interactions: From the Brain to the Immune System and Vice Versa
Dantzer, R. (2018) · Physiological Reviews · doi:10.1152/physrev.00039.2016 · Cited by 1,073
Troyer, E. A., Kohn, J. N., & Hong, S. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.027 · Cited by 964 · cited 8×
“In this context, neuroinflammation and subsequent BBB disruption, neurotransmission impairment, HPA axis dysfunction, microglia activation, and indoleamine 2,3-dioxygenase (IDO) induction, all represent interaction pathways between SARS-CoV-2 infection and psychopathological mechanisms underpinning depressive disorder…”
BackgroundInfluentialLiu, Y., Ho, R. C.-M., & Mak, A. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.003 · Cited by 948
Zubair, A. S., McAlpine, L. S., Gardin, T., Farhadian, S., Kuruvilla, D. E., & Spudich, S. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2065 · Cited by 923
Townsend, L., Dyer, A. H., Jones, K., Dunne, J., Mooney, A., Gaffney, F., O'Connor, L., Leavy, D., O'Brien, K., Dowds, J., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0240784 · Cited by 911
Maes, M., Yirmyia, R., Noraberg, J., Brene, S., Hibbeln, J., Perini, G., Kubera, M., Bob, P., Lerer, B., & Maj, M. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9118-1 · Cited by 894
The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis
Deng, J., Zhou, F., Hou, W., Silver, Z., Wong, C. Y., Chang, O., Huang, E., & Zuo, Q. K. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14506 · Cited by 771 · cited 9×
“Our inspection revealed that the prevalence of clinically relevant depressive symptoms among COVID-19 survivors mainly ranged from 21% [8] up to 45% [18].”
BackgroundMethodResultInfluentialNeuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
Nasserie, T., Hittle, M., & Goodman, S. N. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11417 · Cited by 702
Integrating neuroimmune systems in the neurobiology of depression
Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.69 · Cited by 668
Raadsheer, F. C., Hoogendijk, W. J. G., Stam, F. C., Tilders, F. J. H., & Swaab, D. F. (2008) · Neuroendocrinology · doi:10.1159/000126778 · Cited by 667
Enache, D., Pariante, C. M., & Mondelli, V. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.015 · Cited by 615 · cited 1×
“Accordingly, increased microglial activation in association with high levels of IL-6 and TNF-α have been observed in MDD episodes [82], whereas microglia activation has been implicated in both acute and chronic neurological complications of COVID-19 [83], and increased microglial activation has been demonstrated in po…”
BackgroundSexual-dimorphism in human immune system aging
Márquez, E. J., Chung, C.-H., Marches, R., Rossi, R. J., Nehar-Belaid, D., Eroglu, A., Mellert, D. J., Kuchel, G. A., Banchereau, J., & Ucar, D. (2020) · Nature Communications · doi:10.1038/s41467-020-14396-9 · Cited by 584 · cited 1×
“Moreover, males tend to express a stronger age-dependent activation of the innate pro-inflammatory pathways [123], leading to higher chronic subclinical systemic inflammation than that observed in females [124].”
BackgroundGlucocorticoids, cytokines and brain abnormalities in depression
Zunszain, P. A., Anacker, C., Cattaneo, A., Carvalho, L. A., & Pariante, C. M. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.04.011 · Cited by 554
Mazza, M. G., Palladini, M., De Lorenzo, R., Magnaghi, C., Poletti, S., Furlan, R., Ciceri, F., Rovere-Querini, P., & Benedetti, F. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2021.02.021 · Cited by 513 · cited 6×
“Interestingly, two studies found that reducing inflammatory markers over time predicted improvement of depressive symptoms at follow-up [10, 98].”
BackgroundInfluentialSelf-citationLenze, E. J., Mattar, C., Zorumski, C. F., Stevens, A., Schweiger, J., Nicol, G. E., Miller, J. P., Yang, L., Yingling, M., Avidan, M. S., et al. (2020) · JAMA · doi:10.1001/jama.2020.22760 · Cited by 495
Wang, J., Wu, X., Lai, W., Long, E., Zhang, X., Li, W., Zhu, Y., Chen, C., Zhong, X., Liu, Z., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017173 · Cited by 486
Köhler, C. A., Freitas, T. H., Stubbs, B., Maes, M., Solmi, M., Veronese, N., de Andrade, N. Q., Morris, G., Fernandes, B. S., Brunoni, A. R., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-017-0632-1 · Cited by 449 · cited 1×
“Antidepressants may decrease peripheral markers of inflammation including IL-6, IL-10, TNF-α, and CCL-2, notably associated both with COVID-19 and with depression severity [137, 147].”
BackgroundNervous system consequences of COVID-19
Spudich, S., & Nath, A. (2022) · Science · doi:10.1126/science.abm2052 · Cited by 437
Guo, Q., Zheng, Y., Shi, J., Wang, J., Li, G., Li, C., Fromson, J. A., Xu, Y., Liu, X., Xu, H., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.038 · Cited by 406 · cited 3×
“Specifically, post-COVID-19 depressive symptoms were found to be associated with NLR in four studies [112, 115–117], with CRP in four studies [34, 98, 113, 115], with systemic inflammation index (SII) in three studies [10, 13, 26], with the neutrophil count in two studies [115, 117], and with IL-6 in two studies [34,…”
BackgroundThe experience of quarantine for individuals affected by SARS in Toronto
Cava, M. A., Fay, K. E., Beanlands, H. J., McCay, E. A., & Wignall, R. (2005) · Public Health Nursing · doi:10.1111/j.0737-1209.2005.220504.x · Cited by 394 · cited 1×
“Moreover, quarantine for infected patients also leads to loneliness and social isolation [99, 100].”
BackgroundPariante, C. M. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.04.001 · Cited by 382 · cited 1×
“However, high levels of glucocorticoids may, in the long term, cause resistance to glucocorticoid feedback on the HPA axis, thus allowing pro-inflammatory signaling pathways to avoid normal feedback inhibition [90].”
BackgroundNeurobiology and consequences of social isolation stress in animal model—A comprehensive review
Mumtaz, F., Khan, M. I., Zubair, M., & Dehpour, A. R. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.086 · Cited by 369 · cited 1×
“Evidence from animal models has shown that social isolation alters activity, neurochemical function, and the neuroendocrine system, inducing pathological behavior and symptoms of anxiety, depression, and memory loss [101].”
BackgroundImmune suppression and immune activation in depression
Blume, J., Douglas, S. D., & Evans, D. L. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.008 · Cited by 338
Neutrophil/lymphocyte ratio and platelet/lymphocyte ratio in mood disorders: A meta-analysis
Mazza, M. G., Lucchi, S., Tringali, A. G. M., Rossetti, A., Botti, E. R., & Clerici, M. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.012 · Cited by 326 · cited 1×
“To date, several studies have proven their utility as inflammatory biomarkers of MDD episodes [125, 126].”
BackgroundSelf-citationDepression's Unholy Trinity: Dysregulated Stress, Immunity, and the Microbiome
Cruz-Pereira, J. S., Rea, K., Nolan, Y. M., O'Leary, O. F., Dinan, T. G., & Cryan, J. F. (2020) · Annual Review of Psychology · doi:10.1146/annurev-psych-122216-011613 · Cited by 320 · cited 11×
“The peripheral inflammatory mediators such as cytokines, chemokines, and acute-phase protein reach the CNS passing through a disrupted blood-brain barrier (BBB) [16, 46].”
BackgroundInfluentialKynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301 · cited 1×
“Increases in kynurenine and decreases in tryptophan have been observed in patients with MDD episodes [74, 75].”
BackgroundFernandes, B. S., Steiner, J., Molendijk, M. L., Dodd, S., Nardin, P., Gonçalves, C.-A., Jacka, F., Köhler, C. A., Karmakar, C., Carvalho, A. F., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30370-4 · Cited by 247 · cited 1×
“To date, several studies have proven their utility as inflammatory biomarkers of MDD episodes [125, 126].”
BackgroundAnti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells
Liu, D., Wang, Z., Liu, S., Wang, F., Zhao, S., & Hao, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.033 · Cited by 221 · cited 1×
“Furthermore, in the CNS, SSRIs inhibit microglial activation and decrease cytokine production by these cells [148].”
BackgroundXin, M., Luo, S., She, R., Yu, Y., Li, L., Wang, S., Ma, L., Tao, F., Zhang, J., Zhao, J., et al. (2020) · American Psychologist · doi:10.1037/amp0000692 · Cited by 215 · cited 1×
“Moreover, quarantine for infected patients also leads to loneliness and social isolation [99, 100].”
BackgroundCarpinteiro, A., Edwards, M. J., Hoffmann, M., Kochs, G., Gripp, B., Weigang, S., Adams, C., Carpinteiro, E., Gulbins, A., Keitsch, S., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100142 · Cited by 184
Zhou, Y., Hou, Y., Shen, J., Mehra, R., Kallianpur, A., Culver, D. A., Gack, M. U., Farha, S., Zein, J., Comhair, S., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000970 · Cited by 180
Factors related to mental health of inpatients with COVID-19 in Wuhan, China
Hu, Y., Chen, Y., Zheng, Y., You, C., Tan, J., Hu, L., Zhang, Z., & Ding, L. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.07.016 · Cited by 175
Lu, Y., Ho, C. S., Liu, X., Chua, A. N., Wang, W., McIntyre, R. S., & Ho, R. C. (2017) · PLOS ONE · doi:10.1371/journal.pone.0186700 · Cited by 164 · cited 3×
“SSRI activation of the S1R is associated with an anti-inflammatory action through the downregulation of cytokine production including IL-6, IL-8, IL-1β, and IL-12 [136, 137].”
BackgroundNeurological and cognitive sequelae of COVID-19: a four month follow-up.
Mattioli, F., Stampatori, C., Righetti, F., Sala, E., Tomasi, C., & De Palma, G. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10579-6 · Cited by 160
Neuropathobiology of COVID-19: The Role for Glia
Tremblay, M.-E., Madore, C., Bordeleau, M., Tian, L., & Verkhratsky, A. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592214 · Cited by 159 · cited 1×
“Accordingly, increased microglial activation in association with high levels of IL-6 and TNF-α have been observed in MDD episodes [82], whereas microglia activation has been implicated in both acute and chronic neurological complications of COVID-19 [83], and increased microglial activation has been demonstrated in po…”
BackgroundInflammatory cytokines influence measures of white matter integrity in Bipolar Disorder
Benedetti, F., Poletti, S., Hoogenboezem, T. A., Mazza, E., Ambrée, O., de Wit, H., Wijkhuijs, A. J. M., Locatelli, C., Bollettini, I., Colombo, C., et al. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.05.047 · Cited by 151
Self-citationPeripheral and central kynurenine pathway abnormalities in major depression
Paul, E. R., Schwieler, L., Erhardt, S., Boda, S., Trepci, A., Kämpe, R., Asratian, A., Holm, L., Yngve, A., Dantzer, R., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.01.002 · Cited by 134
Lithium and suicide prevention in mood disorders and in the general population: A systematic review
Del Matto, L., Muscas, M., Murru, A., Verdolini, N., Anmella, G., Fico, G., Corponi, F., Carvalho, A. F., Samalin, L., Carpiniello, B., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.06.017 · Cited by 120
Turrin, N. P., & Rivest, S. (2004) · Experimental Biology and Medicine · doi:10.1177/153537020422901003 · Cited by 107 · cited 1×
“Glucocorticoids then act as negative feedback on the inflammatory response [89] to avoid the deleterious effects of excessive production of inflammatory mediators.”
BackgroundIda, T., Hara, M., Nakamura, Y., Kozaki, S., Tsunoda, S., & Ihara, H. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2007.12.047 · Cited by 107
Correlation between immune response and self-reported depression during convalescence from COVID-19
Yuan, B., Li, W., Liu, H., Cai, X., Song, S., Zhao, J., Hu, X., Li, Z., Chen, Y., Zhang, K., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.05.062 · Cited by 105 · cited 1×
“Specifically, post-COVID-19 depressive symptoms were found to be associated with NLR in four studies [112, 115–117], with CRP in four studies [34, 98, 113, 115], with systemic inflammation index (SII) in three studies [10, 13, 26], with the neutrophil count in two studies [115, 117], and with IL-6 in two studies [34,…”
Biomarkers of post-covid depression
Lorkiewicz, P., & Waszkiewicz, N. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10184142 · Cited by 102 · cited 1×
“0001), and correlated positively with disease severity [76], but its role has not yet been investigated in the pathogenesis of post-COVID-19 depression.”
BackgroundLithium in the treatment of major depressive disorder
Bschor, T. (2014) · Drugs · doi:10.1007/s40265-014-0220-x · Cited by 94
Can Cytokine Blocking Prevent Depression in COVID-19 Survivors?
Benedetti, F., Mazza, M., Cavalli, G., Ciceri, F., Dagna, L., & Rovere-Querini, P. (2021) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09966-z · Cited by 55
Self-citationAntidepressant psychopharmacology: is inflammation a future target?
Benedetti, F., Zanardi, R., & Mazza, M. G. (2022) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000403 · Cited by 45 · cited 1×
“Anti-inflammatory drugs and immunomodulators that are currently being tested for treatment-resistant MDD and that have proved efficacious in reducing depressive symptoms in patients with inflammation could prove useful for inflammation-induced depressive episodes both as prevention and as a treatment strategy [186].”
BackgroundSelf-citationFluvoxamine, melatonin and COVID-19
Anderson, G. M. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05753-z · Cited by 21
Metadata
- Authors
- Mazza, M. G., Palladini, M., Poletti, S., & Benedetti, F.
- Venue
- CNS Drugs
- Published
- 2022-06-21
- Volume
- 36
- Issue
- 7
- Pages
- 681-702
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W4283260453
- Cited by
- 220
- References
- 75
- FWCI
- 22.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.